Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression
Authors:
Open Access
- 28 September 2006
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 17 (11) , 1625-1630
Abstract
Background: Celecoxib is a selective cyclooxygenase-2 inhibitor with antitumor and antiangiogenic activity. We sought to determine pharmacodynamic change in tumors of patients with nasopharyngeal carcinoma (NPC) treated with celecoxib. Methods: Tumor biopsies were obtained before and after treatment with celecoxib 400 mg b.i.d. for 14 days in patients with newly diagnosed, untreated NPC. Tumor angiogenesis and cell proliferation were assessed by immunohistochemistry and gene expression by microarray analysis. Plasma celecoxib concentrations were obtained on days 8 and 14. Results: Paired samples were analyzed in 15 patients. Microvessel density was reduced in post-treatment samples and mean celecoxib levels reached therapeutic levels. Thirty-five genes (27 down-regulated, eight up-regulated) were differentially expressed on microarray analysis (p < 0.001). Down-regulated genes included cell cycle regulation-related (cyclin-dependent kinase 2, YES1), transcription factor (TRIP-Br2), whereas the antigen processing and presentation-related gene HLA-DM B was up-regulated. Conclusion: Celecoxib reduced angiogenesis and induced tumor transcriptional changes. Further characterization of these transcriptional changes in vivo is needed to provide further insights into the effects of celecoxib in neoplastic tissue. Our findings provide a rationale for clinical studies aimed at assessing the efficacy of celecoxib in the treatment of NPC.Keywords
This publication has 23 references indexed in Scilit:
- Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implicationsJournal of Clinical Pathology, 2005
- Overexpression of Cyclooxygenase-2 in Nasopharyngeal Carcinoma and Association With Epidermal Growth Factor Receptor ExpressionJAMA Otolaryngology–Head & Neck Surgery, 2005
- Cyclooxygenase-2: A Therapeutic TargetAnnual Review of Medicine, 2002
- Cyclo-oxygenase 2: a pharmacological target for the prevention of cancerThe Lancet Oncology, 2001
- Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic MiceJournal of Biological Chemistry, 2001
- COX-2 is expressed in human pulmonary, colonic, and mammary tumorsCancer, 2000
- The Relationship Between Microvessel Density, the Expression of Vascular Endothelial Growth Factor (VEGF), and the Extension of Nasopharyngeal CarcinomaThe Laryngoscope, 2000
- Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinomaThe Laryngoscope, 1999
- Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)Cell, 1996
- New prognostic factors in nasopharyngeal carcinoma: Tumor angiogenesis and C-erbB2 expressionCancer, 1996